Option chain shows key data for Monopar Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Monopar Therapeutics.

Monopar Therapeutics (NASDAQ:MNPR) Stock, Option Chain

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

movers image

News

Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LENZ

LGVN

MNPR

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

AMZN

GTLB

NVDA

PANW

PLTR

RKLB

SERV

SOFI

TSLA

UBER

Equities were mixed this week; the Dow turned lower, but the S&amp;P and the NASDAQ finished higher. In fact, the NASDAQ hit a record high on Friday buoyed by the strong earnings report from Tesla.  
Overall,

MarketBeat Week in Review – 10/21- 10/25

Monopar Therapeutics Inc

<p>RBC Capital  analyst Kenneth Lee   reiterates Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Outperform and maintains $13 price target.</p>


Price Target

Reiteration

Analyst Ratings

RITM

RBC Capital Reiterates Outperform on Rithm Capital, Maintains $13 Price Target


<p><strong>POSaBIT Systems Corporation </strong>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/POSAF#OTCQX">POSAF</a>), a provider of payments and point-of-sale infrastructure for the cannabis industry, has integrated Metrc Connect reporting in its point-of-sale system for all states that utilize the track and trace system. Metrc, a U.S.-based provider of cannabis regulatory technology systems, combines software, radio-frequency identification (RFID), customer support, and a secure database to track cannabis from growth, harvest, and processing to testing and transport.</p>
<p>"We are excited that POSaBIT has achieved full integration with Metrc Connect across all States, including Oregon," stated <strong>Michael Johnson,</strong> CEO of Metrc. "POSaBIT's commitment to adopt Metrc Connect highlights their dedication to providing a smooth transition and optimal experience for their customers."</p>
<p>All POSaBIT partner dispensaries in Metrc regions now report necessary data to their regulatory bodies through the company's point-of-sale software.</p>
<p><strong>Read Also: </strong><a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<p><strong>Ryan Hamlin</strong>, CEO/co-founder of POSaBIT, commented, "We have partnered closely with Metrc over the years and we appreciate their industry leadership when it comes to compliance. This continued focus on compliance and regulatory requirements by POSaBIT has proven to be one of the main reasons so many merchants have migrated over from older legacy Point of Sale providers to a more innovative POSaBIT POS solution."</p>
<p>Earlier this month, Metrc <a href="https://www.benzinga.com/markets/cannabis/24/11/41689697/metrc-to-support-virginias-regulation-of-medical-marijuana-market-signs-new-track-and-trace-gove">signed a contract</a> with the Commonwealth of Virginia to support the regulation of its medical cannabis market. Metrc&#8217;s track-and-trace platform provides transparency to ensure regulatory compliance, help combat the illicit market and safeguard the health and well-being of Virginia&#8217;s patients. The Metrc system allows licensed operators to track activities affecting a plant&#8217;s status or the creation of cannabis-based products, including origin, testing results, handling, and chain-of-custody information via the company's RFID tracking model and software-as-a-service (SaaS) system. The information is then easily accessible to state regulators.</p>
<p>Metrc is engaged in 27 government contracts and serves more than 500,000 users, including growers, testing facilities, dispensaries, state regulators and law enforcement officials.</p>
<p><strong>Price Action </strong></p>
<p><strong>POSaBit shares closed Wednesday&#8217;s market session flat at $0.081 per share. </strong></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39293215/metrc-enters-track-and-trace-cannabis-contract-with-a-tribal-government-via-partnership-with-cal"><strong>Metrc Enters Track-And-Trace Cannabis Contract With A Tribal Government Via Partnership With California Native American Tribe</strong></a></li>
<li></li>
</ul>
<p><em>Photo: Courtesy of Plateresca via Shutterstock</em></p>


Cannabis

POSAF

Cannabis Fintech POSaBIT Integrates Metrc Connect Reporting

<p>Citigroup  analyst Keith Horowitz   maintains Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Neutral and raises the price target from $485 to $585.</p>


Citigroup Maintains Neutral on Goldman Sachs Gr, Raises Price Target to $585

WIIM

The S&P and Nasdaq are lower as Nvidia falls after its quarterly earnings report.

CATX

Perspective Therapeutics shares are trading lower. The company announced initial results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET.

<p>RBC Capital  analyst Matthew Hedberg   maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $175 to $188.</p>


SNOW

RBC Capital Maintains Outperform on Snowflake, Raises Price Target to $188

<p>Lake Street  analyst Eric Martinuzzi   maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Buy and raises the price target from $19 to $22.</p>


Lake Street Maintains Buy on Universal Technical, Raises Price Target to $22

<p>B of A Securities  analyst Bradley Sills   maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Neutral and raises the price target from $160 to $185.</p>


B of A Securities Maintains Neutral on Snowflake, Raises Price Target to $185

NOEMU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

DYNXU

<p>The Alabama Court of Civil Appeals rejected the Alabama Medical Cannabis Commission's (AMCC) attempt to dismiss a lawsuit filed by a medical marijuana operator, challenging its already troubled medical cannabis licensing process.</p>
<h3 class="wp-block-heading">What Happened</h3>
<p>Jemmstone Alabama, LLC, filed the lawsuit in December 2023, alleging mismanagement and improper denial of its application for an integrated medical cannabis facility license, <a href="https://www.alreporter.com/2024/11/18/court-rejects-amccs-bid-to-dismiss-lawsuit-medical-cannabis-in-limbo/">reported</a> Alabama Political Reporter.</p>
<p>In the lawsuit, Jemmstone initially named AMCC only as a defendant, in the caption of the complaint. However, throughout the document, the plaintiff consistently referenced individual commissioners.</p>
<p>The AMCC sought to take advantage of this procedural&nbsp;detail, insisting the absence of commissioners from the caption made the complaint invalid under the Alabama Rules of Civil Procedure.</p>
<p>The commission argued that the lawsuit should be dismissed on jurisdictional grounds, claiming sovereign immunity.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/39989148/real-life-american-hero-and-veteran-cant-get-his-medicine-as-alabama-medical-cannabis-legal-saga">‘Real-Life American Hero' And Veteran Can't Get His Medicine As Alabama Medical Cannabis Legal Saga Continues, Activists Say Enough Already</a></strong></p>
<p>The appellate court ruled that the omission of commissioners&#8217; names from the caption was a technical error, rejecting AMCC's claim of sovereign immunity and allowing the lawsuit to proceed.</p>
<p>The court also rejected the AMCC&#8217;s claim that improper service of process made the case invalid.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading">What's Next</h3>
<p>The case now proceeds in the Montgomery Circuit Court.</p>
<p>The medical marijuana program was legalized in 2021 in Alabama. However, its implementation has been postponed due to ongoing legal challenges.</p>
<p>So far, AMCC managed to award, but not issue licenses to businesses that have applied to enter the state's medical market.</p>
<p>In December 2023, the Alabama cannabis regulator awarded 20 medical cannabis licenses for the production, distribution, dispensing and testing of medical marijuana (MMJ) as well as five of the most coveted permits – the integrated facility licenses, which allow for vertical integration. This move came after several failed attempts to allocate licenses.</p>
<p>Read Next:</p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40735369/new-hope-for-alabama-medical-marijuana-program-as-judge-considers-revising-licensing-restriction"><strong>New Hope For Alabama Medical Marijuana Program As Judge Considers Revising Licensing Restrictions</strong></a></li>
</ul>


Legal

Alabama Lawsuit Against Cannabis Regulator Over Medical Marijuana Licensing Moves Forward

<p>RBC Capital  analyst Sean Dodge   reiterates Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) with a Outperform and maintains $17 price target.</p>


RBC Capital Reiterates Outperform on Sotera Health, Maintains $17 Price Target

<p>B of A Securities  analyst Tal Liani   maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Neutral and raises the price target from $400 to $430.</p>


B of A Securities Maintains Neutral on Palo Alto Networks, Raises Price Target to $430

Macro Economic Events

Econ #s

Economics

USA Natural Gas Storage -3B Vs 2B Est.; 42B Prior

<p><a href="https://thebearcave.substack.com/p/problems-at-transdigm-tdg" title="https://thebearcave.substack.com/p/problems-at-transdigm-tdg">https://thebearcave.substack.com/p/problems-at-transdigm-tdg</a></p>


Short Sellers

Trading Ideas

Watching TransDigm; The Bear Cave Research Issues Report Titled "Problems at TransDigm"

<p>Deep-pocketed investors have adopted a bearish approach towards ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COP usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for ConocoPhillips. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $60,600, and 6 are calls, amounting to $730,955.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $135.0 for ConocoPhillips over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ConocoPhillips's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ConocoPhillips's substantial trades, within a strike price spectrum from $115.0 to $135.0 over the preceding 30 days.</p>
<h3>ConocoPhillips Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203127_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$450.0K</td>
<td align="right">61</td>
<td>1.8K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$116.1K</td>
<td align="right">61</td>
<td>2.2K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$59.4K</td>
<td align="right">61</td>
<td>375</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.0</td>
<td>$2.99</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$47.1K</td>
<td align="right">61</td>
<td>2.4K</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.4</td>
<td>$7.05</td>
<td>$7.4</td>
<td>$115.00</td>
<td>$34.0K</td>
<td align="right">208</td>
<td>46</td>
</tr>
</tbody>
</table>
</p>
<h3>About ConocoPhillips</h3>
<p>ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.</p>
<h3>Present Market Standing of ConocoPhillips</h3>
<ul>
<li>Currently trading with a volume of 705,190, the COP's price is up by 1.46%, now at $115.09. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About ConocoPhillips</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $139.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for ConocoPhillips, targeting a price of $132.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on ConocoPhillips, which currently sits at a price target of $148.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on ConocoPhillips with a target price of $137. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ConocoPhillips options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

Looking At ConocoPhillips's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Iris Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IREN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Iris Energy.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 41% bullish and 52%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $817,500, and 13 are calls, for a total amount of $738,926.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $6.0 to $18.0 for Iris Energy over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Iris Energy's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Iris Energy's significant trades, within a strike price range of $6.0 to $18.0, over the past month.</p>
<h3>Iris Energy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203121_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.6</td>
<td>$9.00</td>
<td>$320.0K</td>
<td>5.4K</td>
<td>4.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$9.00</td>
<td>$310.2K</td>
<td>5.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.6</td>
<td>$1.6</td>
<td>$9.00</td>
<td>$160.0K</td>
<td>5.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.55</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$18.00</td>
<td>$150.1K</td>
<td>8.9K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$8.00</td>
<td>$120.5K</td>
<td>2.2K</td>
<td>295</td>
</tr>
</tbody>
</table>
</p>
<h3>About Iris Energy</h3>
<p>Iris Energy Ltd is a Bitcoin mining company. It builds, owns, and operates data centers and electrical infrastructure for the mining of Bitcoin powered by renewable energy. The company's mining operations generate revenue by earning Bitcoin through a combination of block rewards and transaction fees from the operation of its specialized computers called Application-specific Integrated Circuits and exchanging these Bitcoin for currencies such as USD or CAD on a daily basis.</p>
<p>Following our analysis of the options activities associated with Iris Energy, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Iris Energy</h3>
<ul>
<li>Currently trading with a volume of 10,433,826, the IREN's price is down by -5.15%, now at $9.58. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 5 days.</li>
</ul>
<h3>Expert Opinions on Iris Energy</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $20. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iris Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


IREN

Smart Money Is Betting Big In IREN Options

<p>Deep-pocketed investors have adopted a bearish approach towards Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Deere. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 35% leaning bullish and 45% bearish. Among these notable options, 16 are puts, totaling $779,083, and 4 are calls, amounting to $204,500.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $460.0 for Deere, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Deere's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Deere's whale trades within a strike price range from $380.0 to $460.0 in the last 30 days. </p>
<h3>Deere 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203115_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.8</td>
<td>$14.9</td>
<td>$16.8</td>
<td>$420.00</td>
<td>$100.8K</td>
<td>1.5K</td>
<td align="right">176</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.0</td>
<td>$16.95</td>
<td>$17.0</td>
<td>$420.00</td>
<td>$85.0K</td>
<td>454</td>
<td align="right">260</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$16.65</td>
<td>$13.55</td>
<td>$14.79</td>
<td>$420.00</td>
<td>$81.1K</td>
<td>454</td>
<td align="right">310</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$18.75</td>
<td>$15.4</td>
<td>$18.75</td>
<td>$420.00</td>
<td>$65.6K</td>
<td>454</td>
<td align="right">85</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.35</td>
<td>$14.45</td>
<td>$16.35</td>
<td>$430.00</td>
<td>$52.3K</td>
<td>112</td>
<td align="right">163</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<p>After a thorough review of the options trading surrounding Deere, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Deere</h3>
<ul>
<li>With a trading volume of 1,145,107, the price of DE is up by 5.35%, reaching $426.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Deere with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


This Is What Whales Are Betting On Deere

<p>Bringing Extensive Financial Expertise To Support Growth And Enhance Shareholder Value</p>


Management

UAVS

AgEagle Aerial Systems Appoints Adrienne Anderson As Interim CFO

Market Summary

General

$BTC

Benzinga Market Summary: Nvidia Shares Fall After Earnings Report, Initial Jobless Claims Come In Below Estimates, Snowflake Stock Surges On Earnings Report, Bitcoin Rises Above $98,000

Monopar stock climbs as it takes over Wilson disease drug candidate

Monopar Therapeutics (MNPR) announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the sha...

Monopar Therapeutics announces common stock offering, no amount given

Monopar Therapeutics proposes public offering of common stock

Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share

Rodman & Renshaw acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving ...

Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25

Monopar Therapeutics Inc ( ($MNPR) ) just unveiled an announcement. Monopar Therapeutics Inc., a biotech firm focused on innovative treatments, suc...

Monopar Therapeutics Closes $19.2 Million Stock Offering

Cash and cash equivalents as of September 30, 2024, were $6.0 million. As noted above, the Company completed a registered public offering on Octobe...

Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)

Monopar Therapeutics GAAP EPS of -$0.37

JonesResearch raised the firm's price target on Monopar Therapeutics (MNPR) to $37 from $9 and keeps a Buy rating on the shares post the Q3 report....

Monopar Therapeutics price target raised to $37 from $9 at JonesResearch

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Monopar Therapeutics Inc (MNPR – Research Report). The associated price ta...

Monopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson's Disease Treatment

Biotech

Press Releases

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Health Care

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

IPOs

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Financing

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Earnings

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Comments

Monopar Therapeutics

Monopar Therapeutics (MNPR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga